Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eaton Vance Ohio Municipal Income Trust (NQ: EVO )

5.034 -0.066 (-1.29%)
Streaming Delayed Price Updated: 2:23 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eaton Vance Ohio Municipal Income Trust

< Previous 1 2 3 Next >
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
Via ACCESSWIRE
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
Via ACCESSWIRE
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
Via ACCESSWIRE
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
Via ACCESSWIRE
Evotec welcomes Aurélie Dalbiez as Chief People Officer
Via ACCESSWIRE
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
Via ACCESSWIRE
Evotec SE: Invitation to Conference Call
Via ACCESSWIRE
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
Via ACCESSWIRE
Evotec and Crohn's & Colitis Foundation Enter Agreement to Advance Drug Discovery for Novel IBD Therapies
Via ACCESSWIRE
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb
Via ACCESSWIRE
Evotec and Owkin Enter an A.I.-Powered Strategic Partnership to Accelerate Therapeutics Pipeline in Oncology and I&I
Via ACCESSWIRE
Evotec Announces CEO Transition
Via ACCESSWIRE
Evotec receives US$ 2.5 M Grant to Leverage Human iPSC-Derived Teratogenicity Platform for Global Health Programmes
Via ACCESSWIRE
Evotec Enters Partnership with Charité to Expand Molecular Patient Database in Autoimmune Diseases
Via ACCESSWIRE
Evotec-partner Jingxin Receives Approval for EVT201 in China
Via ACCESSWIRE
Evotec Presents Precision Medicine Platforms for Accelerated Pipeline Building at Capital Markets Day
Via ACCESSWIRE
Evotec SE Reports Results for the First Nine Months 2023 and Provides Corporate Update
Via ACCESSWIRE
Evotec and Dewpoint Therapeutics Enter Strategic Partnership in Oncology
Via ACCESSWIRE
Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'
Via ACCESSWIRE
Evotec SE: Launch of Partnering Agreement to Strengthen Biotech Innovators in Shared R&D Economy
Via ACCESSWIRE
Evotec and Novo Nordisk Launch LAB eN² to Accelerate Translation in Cardiometabolic Diseases
Via ACCESSWIRE
Evotec SE Reports Results for the First Half-year 2023 and Provides Corporate Updates
Via ACCESSWIRE
Evotec SE Reports First Half-Year 2023 Results on 29 August 2023
Via ACCESSWIRE
Evotec Provides Update on Financial Impact of Cyber-Attack
Via ACCESSWIRE
Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership
Via ACCESSWIRE
Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program
Via ACCESSWIRE
Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme
Via ACCESSWIRE
Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items
Via ACCESSWIRE
Evotec Presents Sustainability Strategy
Via ACCESSWIRE
Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics
Via ACCESSWIRE
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.